Last updated on October 9, 2019
A Pennsylvania jury ruled Tuesday that US pharmaceutical giant Johnson & Johnson have to pay $8 billion in damages and interest for failing to warn a psychiatric medication could lead to breast development in men.
Johnson & Johnson and its subsidiary Janssen Pharmaceuticals were blamed as plaintiff Nicholas Murray advised the Philadelphia court the medication Risperdal, prescribed to treat schizophrenia and bipolar disease, had forced him to develop breasts.
The business contested the judgment in a statement, calling the compensation awarded”grossly disproportionate” together with the first award in the instance of $680,000.
“The company is convinced (the judgment ) will probably be overturned,” the announcement said, and”will probably be moving to put aside this surplus and unfounded verdict”
The business is facing a set of complaints from state courts for failing to warn of Risperdal’s negative effects, such as in Pennsylvania, California, and Missouri.
Risperdal, accepted for treating adults from the US Food and Drug Administration in 1993, brought in some $737 million (672 million euros) in earnings in 2018.